279: Why Nanovesicles Outperform Exosomes: Scalable Drug Delivery Beyond Injectable Vaccines with Christopher Locher - Part 1

What if the best way to unlock durable, broad-spectrum immunity is to rethink the very vessels delivering our vaccines?While much of the industry focuses on refining existing delivery systems, Christopher Locher is charting a new course—one inspired by nature’s own couriers. Imagine a future where oral vaccines and modular, on-demand manufacturing aren’t just possibilities, but standard practice.Christopher Locher, CEO and Co-founder of Versatope Therapeutics, brings decades of experience in drug discovery from Vertex Pharmaceuticals, Opsona Therapeutics, and Maxigen. In this episode, he shares his journey from high school science classrooms to the helm of a company pioneering recombinant extracellular transport vesicles—nanovesicles that promise to transform vaccine delivery and immunomodulation.Topics discussed:How basic scientific curiosity and the inspiration from teachers sparked Christopher's career in biotechnology (03:39)The unmet needs in vaccine development for infectious and parasitic diseases, especially in regions below the equator (04:17)Engineering nanovesicles as immunomodulators and drug delivery vehicles, using microbial bioreactors for production (06:38)Co-producing proteins and vesicles in a single process, and the flexibility of the platform (08:28)Key benefits of Versatope's platform, such as cost efficiency, stability, and commercial scalability compared to mammalian exosomes (09:53)Prospects for multi-specific vaccines and the future direction for scalable bioprocessing (11:47)Adapting manufacturing processes and overcoming logistical challenges—from COVID-related shutdowns to supply chain bottlenecks (12:21)Strategies for navigating evolving regulatory requirements with agencies like the FDA, and experience with fast IND allowance (14:53)Analytical and characterization challenges of complex nanovesicle-based products versus simpler platforms like antibodies (17:30)The vision for decentralized or local vaccine manufacturing, especially in resource-limited settings (19:12)Smart insight: Christopher Locher highlighted that the FDA allowed their IND submission for a universal influenza vaccine in less than a month after review—and notably, with no hold clinical questions—when it was submitted just before the Christmas holidays and allowed on January 19th, 2025. This rapid regulatory turn-around was made possible by a strong regulatory team and collaborative CDMO efforts, showcasing how innovative platforms and well-prepared submissions can accelerate early-stage clinical development in biotech.If Christopher's vesicle platform has you thinking about building a novel modality on an unconventional host, these four episodes go deeper on alternative production systems, microbial scale-up, and the CMC and cost decisions that get a first-in-class biologic to patients.Episodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi OsawaEpisodes 239 - 240: Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes with Juergen MairhoferEpisodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri KornmannEpisodes 267 - 268: Why Affordable Insulin Is a Money Problem, Not a Science Problem with Eric MoyalConnect with Christopher Locher:Website: www.versatope.com LinkedIn: www.linkedin.com/in/christopher-locher-biotechSupport the show